Compare NRDY & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRDY | CNTB |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 135.7M |
| IPO Year | 2020 | 2020 |
| Metric | NRDY | CNTB |
|---|---|---|
| Price | $0.86 | $2.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.00 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 769.7K | 287.7K |
| Earning Date | 05-07-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.16 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | $4.88 | N/A |
| Revenue Next Year | $10.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.75 | $1.23 |
| 52 Week High | $1.74 | $3.82 |
| Indicator | NRDY | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 53.42 |
| Support Level | $0.78 | $2.03 |
| Resistance Level | $0.99 | $2.68 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 43.55 | 89.74 |
Nerdy Inc operate a next-generation live tutoring and intervention platform that leverages the power of human expertise with Developed artificial intelligence (AI) to personalize learning, accelerate student achievement, and empower educators. The company's proprietary platform leverages technology, including AI, to connect learners with instructors across a wide range of subjects and formats, including subscription-based learning, one-on-one instruction, small group tutoring, large-format classes, and assessments. Its flagship business operates under the Varsity Tutors brand. The company's offerings are available directly to students and consumers, as well as through schools and other institutions.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.